Eli Lil­ly’s Alzheimer’s trek; No­vo Nordisk puts down US roots; Sarep­ta and gene ther­a­py ac­cel­er­at­ed ap­provals; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Hel­lo March! To round out Feb­ru­ary, we take a deep look at the wind­ing his­to­ry of an Alzheimer’s drug on the brink of ap­proval, US reg­u­la­tors’ lat­est think­ing on ac­cel­er­at­ed ap­provals, next steps for some of the biggest names in phar­ma, and more. Oh, and as of this writ­ing, $XBI is still hov­er­ing above $100 — a thresh­old the in­dex fi­nal­ly crossed this week af­ter a two-year lull.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER